{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"sCR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Overall response was defined according to IMWG criteria as\n\n1. very good partial response (VGPR)\n2. complete response (CR)\n3. stringent complete response (sCR)","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nDexamethasone: Given PO","id":"OG000","title":"Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)"},{"description":"Patients receive lenalidomide PO as in Arm I.\n\nLenalidomide: Given PO","id":"OG001","title":"Arm II (Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 12 months","title":"Overall Response (Number of Participants With VGPR, CR, sCR)","type":"SECONDARY","unitOfMeasure":"Participants"}